SCHEMBL4157410

SCHEMBL4157410

Cn1c(-c2ccc(F)cc2)nc2c(C(=O)O)ccnc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
ADORA3 P0DMS8 3/20 0.45
ADORA1 P30542 3/20 0.45
ADORA2A P29274 2/20 0.45
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
DHODH Q02127 4/20 0.40
ADORA2B P29275 2/20 0.40
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
KDM5A P29375 2/20 0.39
KDM4C Q9H3R0 2/20 0.39
KDM5B Q9UGL1 2/20 0.39
KDM4A O75164 1/20 0.39
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
AHR P35869 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7881518 0.78 ADORA3 (0.48) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL27158261 0.71 GABRA2 (0.41) KDM4EADORA3ADORA1ADORA2ADHODH
SCHEMBL27158560 0.71 GABRA2 (0.41) KDM4EADORA3ADORA1ADORA2ADHODH
SCHEMBL29913098 0.70 KDM5A (0.43) KDM4EDHODHKDM5AKDM4CKDM5B
SCHEMBL27157832 0.70 KDM5A (0.43) KDM4EDHODHKDM5AKDM4CKDM5B
SCHEMBL4066247 0.70 ADORA3 (0.57) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL6660588 0.69 ADORA3 (0.60) ADORA3ADORA1ADORA2AADORA2BPI4KA
SCHEMBL31163636 0.68 PIK3CD (0.45)
SCHEMBL4157107 0.68 DHODH (0.49) DHODHMAPK14
SCHEMBL7880443 0.67 PSEN1 (0.44) ADORA3ADORA1ADORA2AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 KDM4E 1174/4885ADORA3 1875/4885ADORA1 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.